Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:
Roger J. Bedimo, MD, MS
Dr Bedimo reported receiving research grants awarded to his institution from Merck & Co, Inc, and serving on the scientific advisory boards for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, Shionogi, and Janssen Pharmaceuticals. (Updated January 23, 2025)
Constance A. Benson, MD
Dr Benson reported receiving research grants from DNAe Group Holdings, Ltd, and Gilead Sciences, Inc; serving as a consultant to NDA Partners LLC; and serving as a scientific advisory board member for the INTREPID Alliance. (Updated October 7, 2024))
Judith S. Currier, MD
Dr Currier reported consulting or advisor fees from Merck & Co, Inc. (Updated May 9, 2025)
Carlos del Rio, MD
Dr del Rio reported no financial relationships with ineligible companies. (Updated June 5, 2025)
Ellen F. Eaton, MD
Dr Eaton reported receiving consulting fees from Gilead Sciences. (Updated March 1, 2024)
Rajesh T. Gandhi, MD
Dr Gandhi reported no relevant financial relationships with ineligible companies. (Updated April 16, 2025)
Donna M. Jacobsen, BS
Ms Jacobsen reported no relevant financial affiliations with ineligible companies to disclose. (Updated August 13, 2025)
Raphael J. Landovitz, MD
Dr Landovitz reported serving as a consultant for Merck & Co, Inc, and ViiV Healthcare. (Updated July 30, 2025)
Susanna Naggie, MD
Dr Naggie reported consulting fees from Bristol-Myers Squibb, Personal health Insights, Inc, and Vir Biotechnology. She reported having stock options for Vir Biotechnlogy. (Updated March 6, 2024)
Douglas D. Richman, MD
Dr Richman reported consulting or advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and Gilead Sciences, Inc. (Updated January 23, 2024)
Michael S. Saag, MD
Dr Saag reported no relevant financial relationships with ineligible companies (Updated July 14, 2025)
Robert T. Schooley, MD
Dr Schooley reported serving as a consultant for Merck & Co, Inc, SNIPR Biome ApS, BiomX, Inc, Locus Pharmaceuticals, Inc, and Arcturus Therapeutics Holdings, Inc. (Updated June 23, 2025)